Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. RIGL today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 38^th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 7:30am PT in San Francisco, CA. 

To access the live and subsequently archived webcast, go to the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE^® (fostamatinib disodium hexahydrate), the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include a Phase 3 study of fostamatinib in autoimmune hemolytic anemia (AIHA); a recently completed Phase 1 study of R835¹, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program; and an ongoing Phase 1 study of R552¹, a proprietary molecule from its receptor-interacting protein kinase (RIP1) inhibitor program. In addition, Rigel has product candidates in clinical development with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

¹The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Please see www.TAVALISSE.com for full Prescribing Information.

IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com

SOURCE Rigel Pharmaceuticals, Inc.